Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder

A systematic review and meta‐analysis

Datos Bibliográficos

ID23322244
AutoresDavy Vancampfort (0000-0002-4592-8625, UPC KU Leuven, Campus Kortenberg, Department of Neurosciences, KU Leuven ‐ University of Leuven Kortenberg Belgium), Brendon Stubbs (0000-0001-7387-3791, School of Health and Social Care University of Greenwich Eltham London UK), Alex J Mitchell (0000-0001-6014-598X, Department of Psycho‐oncology Leicestershire Partnership NHS Trust Leicester UK), Marc De Hert (0000-0003-4255-5920, UPC KU Leuven, Campus Kortenberg, Department of Neurosciences, KU Leuven ‐ University of Leuven Kortenberg Belgium), Martien Wampers (0000-0003-0414-424X, UPC KU Leuven, Campus Kortenberg, Department of Neurosciences, KU Leuven ‐ University of Leuven Kortenberg Belgium), Philip B Ward (0000-0002-5779-7722, School of Psychiatry University of New South Wales Sydney NSW Australia), Simon Rosenbaum (0000-0002-8984-4941, School of Psychiatry University of New South Wales Sydney NSW Australia), Christoph U Correll (0000-0002-7254-5646, Zucker Hillside Hospital Glen Oaks NY USA)
Año2015
Volumen14
Número3
Páginas339-347
Fecha de publicación2015-10-01
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaWorld Psychiatry (JOURNAL)
Identificadores de la revistaISSN: 1723-8617 • E-ISSN: 2051-5545
EditorialWiley (PUBLISHER • GB)
DOI10.1002/wps.20252
IdiomaEN
Citas recibidas62
Referencias citadas57

Metabolic syndrome (MetS) and its components are highly predictive of cardiovascular diseases. The primary aim of this systematic review and meta‐analysis was to assess the prevalence of MetS and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder, comparing subjects with different disorders and taking into account demographic variables and psychotropic medication use. The secondary aim was to compare the MetS prevalence in persons with any of the selected disorders versus matched general population controls. The pooled MetS prevalence in people with severe mental illness was 32.6% (95% CI: 30.8%‐34.4%; N = 198; n = 52,678). Relative risk meta‐analyses established that there was no significant difference in MetS prevalence in studies directly comparing schizophrenia versus bipolar disorder, and in those directly comparing bipolar disorder versus major depressive disorder. Only two studies directly compared people with schizophrenia and major depressive disorder, precluding meta‐analytic calculations. Older age and a higher body mass index were significant moderators in the final demographic regression model (z = −3.6, p = 0.0003, r 2 = 0.19). People treated with all individual antipsychotic medications had a significantly (p